Phase II trial of nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable melanoma.
P. D. Boasberg
Research Funding - Abraxis BioScience; Genentech
R. W. Weber
Research Funding - Abraxis BioScience; Genentech
S. Cruickshank
Research Funding - Abraxis BioScience; Genentech
O. Hamid
Research Funding - Abraxis BioScience
S. O'Day
Consultant or Advisory Role - Genentech (U); Roche (U)
Research Funding - Abraxis BioScience; Genentech
L. E. Spitler
Stock Ownership - Abraxis BioScience; Genentech